Dutch Robotics Firm Secures €60 Million to Automate Global Blood Collection

2026-03-10 hardware

Utrecht, Tuesday 10 March 2026
Dutch startup Vitestro has secured €60 million to globalise its autonomous blood-drawing robot. Already tested on 10,000 patients, this pioneering technology promises to revolutionise routine medical diagnostics worldwide.

A Substantial Injection of Capital

On 9 March 2026, Vitestro announced the closure of an oversubscribed Series B financing round, raising €60 million (equivalent to $70 million) [1][2][4]. The funding syndicate represents a robust blend of strategic, healthcare, and life sciences investors. New participants include the Labcorp Venture Fund, Mayo Clinic, Sutter Health, InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht [2][7]. They join existing backers such as the European Innovation Council (EIC) Fund, NYBC Ventures, Sonder Capital, and Invest-NL [2][7]. Toon Overbeeke, Vitestro’s Chief Executive Officer and co-founder, noted that the successful close reflects a strong conviction in the company’s mission to establish a new standard in autonomous robotic venous access [2][6].

Engineering the Future of Venous Access

At the core of Vitestro’s offering is the Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™), the first autonomous blood-drawing robot to receive European CE marking [2][7]. The system functions by amalgamating robotics, artificial intelligence, and advanced multimodal imaging—specifically echography or ultrasound—to autonomously identify veins, insert the needle, and collect blood samples [2][7]. Prior to this latest funding milestone, the Aletta® system had already been deployed in clinical and pre-commercial settings across Europe, having been successfully tested on more than 10,000 patients worldwide [2][3].

Strategic International Expansion

The newly secured capital will be channelled into finalising the development of the next-generation Aletta® device, scaling up manufacturing capabilities, and expanding clinical programmes [2][4]. Vitestro is currently focusing on operational and commercial readiness as it prepares for an initial market launch within the Netherlands [1][6]. Following domestic integration, the firm plans a phased commercial rollout across other European markets, beginning with Denmark, before eventually progressing to the United States [alert! ‘Exact timeline for the US commercial launch remains unspecified in current disclosures’] [1][2][7].

Sources & Ecosystem Partners

Medical robotics Series B